Cytokinetics, Incorporated
CYTKNASDAQHealthcare● Active
$69.71
$-1.77(-2.48%)
Market Cap$8.7B
P/E Ratio—
52W High$80.2
52W Low$31.52
Cytokinetics, Incorporated (CYTK) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CYTK · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$1.67
Est. -$1.67 · +0.0%
Revenue
$0.02B
Est. $0.01B · +127.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
CYTK reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$1.64 | — | — | — | $0.02B | — |
| — Q2 FY2026 | May 5, 2026 | -$1.67 | -$1.67 | +0.0% | $0.02B | $0.01B | +127.2% |
| ▼ Q1 FY2026 | Feb 24, 2026 | -$1.48 | -$1.50 | -1.4% | $0.02B | $0.01B | +156.3% |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$1.59 | -$1.54 | +3.1% | $0.00B | $0.01B | -75.9% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$1.34 | -$1.12 | +16.4% | $0.07B | $0.00B | +3131.1% |
| ▲ Q2 FY2025 | May 6, 2025 | -$1.41 | -$1.36 | +3.5% | $0.00B | $0.00B | -43.4% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$1.29 | -$1.26 | +2.3% | $0.02B | $0.01B | +18.7% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -$1.27 | -$1.36 | -7.1% | $0.00B | $0.00B | -77.4% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$1.64
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026
EPS Actual
-$1.67
EPS Est.
-$1.67
EPS Surpr.
+0.0%
Revenue
$0.02B
Q1 FY2026
Feb 24, 2026Miss
EPS Actual
-$1.50
EPS Est.
-$1.48
EPS Surpr.
-1.4%
Revenue
$0.02B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$1.54
EPS Est.
-$1.59
EPS Surpr.
+3.1%
Revenue
$0.00B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$1.12
EPS Est.
-$1.34
EPS Surpr.
+16.4%
Revenue
$0.07B
Q2 FY2025
May 6, 2025Beat
EPS Actual
-$1.36
EPS Est.
-$1.41
EPS Surpr.
+3.5%
Revenue
$0.00B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$1.26
EPS Est.
-$1.29
EPS Surpr.
+2.3%
Revenue
$0.02B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
-$1.36
EPS Est.
-$1.27
EPS Surpr.
-7.1%
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-1.27 | $-0.65 | $-0.34 | 5 |
| Q3 FY2028 | $-4.97 | $-2.55 | $-1.33 | 10 |
| Q2 FY2028 | $-2.19 | $-1.12 | $-0.59 | 7 |
| Q1 FY2028 | $-2.65 | $-1.36 | $-0.71 | 5 |
| Q4 FY2027 | $-1.76 | $-0.91 | $-0.47 | 4 |
| Q3 FY2027 | $-2.37 | $-1.22 | $-0.63 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.1B | 8 |
| Q3 FY2028 | $0.0B | $0.0B | $0.1B | 6 |
| Q2 FY2028 | $0.0B | $0.0B | $0.1B | 5 |
| Q1 FY2028 | $0.0B | $0.0B | $0.1B | 5 |
| Q4 FY2027 | $0.1B | $0.2B | $0.3B | 6 |
| Q3 FY2027 | $0.1B | $0.1B | $0.2B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +0.0% | $66.05 | $77.09 | +16.71% |
| ▼ Q1 FY2026 | Feb 24, 2026 | -1.4% | $68.26 | $70.10 | +2.70% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +3.1% | $59.62 | $59.19 | -0.72% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +16.4% | $35.14 | $35.25 | +0.31% |
| ▲ Q2 FY2025 | May 6, 2025 | +3.5% | $36.67 | $33.97 | -7.36% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +2.3% | $46.86 | $47.45 | +1.26% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -7.1% | $52.52 | $55.50 | +5.67% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -28.4% | $51.22 | $54.00 | +5.43% |
Q2 FY2026+16.71%
Report Date
May 5, 2026
EPS Beat/Miss
+0.0%
Price Before
$66.05
Price After
$77.09
Q1 FY2026+2.70%
Report Date
Feb 24, 2026
EPS Beat/Miss
-1.4%
Price Before
$68.26
Price After
$70.10
Q4 FY2025-0.72%
Report Date
Nov 5, 2025
EPS Beat/Miss
+3.1%
Price Before
$59.62
Price After
$59.19
Q3 FY2025+0.31%
Report Date
Aug 7, 2025
EPS Beat/Miss
+16.4%
Price Before
$35.14
Price After
$35.25
Q2 FY2025-7.36%
Report Date
May 6, 2025
EPS Beat/Miss
+3.5%
Price Before
$36.67
Price After
$33.97
Q1 FY2025+1.26%
Report Date
Feb 27, 2025
EPS Beat/Miss
+2.3%
Price Before
$46.86
Price After
$47.45
Q4 FY2024+5.67%
Report Date
Nov 6, 2024
EPS Beat/Miss
-7.1%
Price Before
$52.52
Price After
$55.50
Q3 FY2024+5.43%
Report Date
Aug 8, 2024
EPS Beat/Miss
-28.4%
Price Before
$51.22
Price After
$54.00
Avg Beat Reaction+2.04%
Avg Miss Reaction+4.60%
Beat Rate5 / 8 quarters
Largest Move+16.71% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CYTK ends December
Cytokinetics, Incorporated (CYTK) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-1.67 (in line with the analyst consensus of $-1.67). The next CYTK earnings date is expected around September 1, 2026.
Each quarter, investors track CYTK earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CYTK revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CYTK's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CYTK earnings · 4 questionsCytokinetics, Incorporated's next earnings report is expected around September 1, 2026. CYTK typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CYTK historically reports after market close (AMC).
CYTK earnings datewhen is CYTK earningsCYTK next earnings datewhen does CYTK report earningsCYTK earnings calendar
▸ Source: FMP · Cytokinetics, Incorporated SEC filings · US GAAP · Cytokinetics, Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026